Personalized Nanomedicine
- 15 September 2012
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (18), 4889-4894
- https://doi.org/10.1158/1078-0432.ccr-12-1414
Abstract
Personalized medicine aims to individualize chemotherapeutic interventions on the basis of ex vivo and in vivo information on patient- and disease-specific characteristics. By noninvasively visualizing how well image-guided nanomedicines—that is, submicrometer-sized drug delivery systems containing both drugs and imaging agents within a single formulation, and designed to more specifically deliver drug molecules to pathologic sites—accumulate at the target site, patients likely to respond to nanomedicine-based therapeutic interventions may be preselected. In addition, by longitudinally monitoring how well patients respond to nanomedicine-based therapeutic interventions, drug doses and treatment protocols can be individualized and optimized during follow-up. Furthermore, noninvasive imaging information on the accumulation of nanomedicine formulations in potentially endangered healthy tissues may be used to exclude patients from further treatment. Consequently, combining noninvasive imaging with tumor-targeted drug delivery seems to hold significant potential for personalizing nanomedicine-based chemotherapeutic interventions, to achieve delivery of the right drug to the right location in the right patient at the right time. Clin Cancer Res; 18(18); 4889–94. ©2012 AACR.Keywords
This publication has 31 references indexed in Scilit:
- Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent mannerNature Nanotechnology, 2012
- Nanomedicine(s) under the MicroscopeMolecular Pharmaceutics, 2011
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft ModelJournal of Nuclear Medicine, 2009
- Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PETJournal of Nuclear Medicine, 2008
- Imaging in the era of molecular oncologyNature, 2008
- The emerging nanomedicine landscapeNature Biotechnology, 2006
- The role of companion diagnostics in the development and use of mutation-targeted cancer therapiesNature Biotechnology, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005